MRP:JSEMr Price Group Limited Analysis
Data as of 2026-05-24 - not real-time
ZAC 15,311.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Mr Price Group is trading at roughly ZAc 15,300, which sits just below its 20‑day SMA (≈15,470) and well under its 50‑day SMA, confirming a short‑term bearish technical bias. However, the DCF‑derived fair value of about ZAc 39,400 suggests an upside of roughly 60%, while the stock boasts a low beta (≈0.10), a solid dividend yield of 5.99% and a payout ratio of 64%, indicating strong cash generation. The company’s fundamentals are robust – revenue is growing at 5.2% YoY, ROE stands near 29%, and free cash flow exceeds ZAc 6.5 bn – and volume has been picking up, supporting liquidity.
On the news side, investor sentiment has been dented by a contentious NKD acquisition in Europe, with a shareholder urging JSE intervention and the stock hitting a 52‑week low amid lingering doubts. Conversely, the Studio 88 athleisure chain has delivered a notable earnings boost, highlighting the group’s growth engines. Balancing the deep valuation gap and dividend appeal against acquisition risk leads to a hold stance in the near term, but a clear buying case for medium‑ and long‑term horizons.
On the news side, investor sentiment has been dented by a contentious NKD acquisition in Europe, with a shareholder urging JSE intervention and the stock hitting a 52‑week low amid lingering doubts. Conversely, the Studio 88 athleisure chain has delivered a notable earnings boost, highlighting the group’s growth engines. Balancing the deep valuation gap and dividend appeal against acquisition risk leads to a hold stance in the near term, but a clear buying case for medium‑ and long‑term horizons.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 4/10
Key Factors
- NKD acquisition uncertainty and recent 52‑week low
- Bearish technical positioning below short‑term SMAs
- Strong support around ZAc 14,753
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation upside versus DCF fair value
- Sustained high dividend yield and solid cash flow
- Growth contribution from Studio 88 and potential synergies from NKD
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Robust ROE and consistent profitability
- Dividend sustainability with a 64% payout ratio
- Long‑run undervaluation and low market beta
Key Metrics & Analysis
Financial Health
Revenue Growth5.20%
Profit Margin9.00%
P/E Ratio10.9
ROE28.55%
ROA11.10%
Debt/Equity61.77
P/B Ratio3.0
Op. Cash FlowZAC8.5B
Free Cash FlowZAC6.6B
Technical Analysis
TrendBearish
RSI45.2
SupportZAC 14,753.00
ResistanceZAC 16,433.00
MA 20ZAC 15,473.35
MA 50ZAC 15,787.02
MA 200ZAC 18,613.66
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61
Valuation
Fair ValueZAC 39,371.13
Target PriceZAC 24,348.66
Upside/Downside59.03%
GradeUndervalued
TypeBlend
Dividend Yield5.99%
Risk Assessment
Beta0.10
Volatility27.27%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.